目錄:MedChemExpress LLC>>生化試劑>> Cilgavimab | MCE
CAS | 2420563-99-9 | 供貨周期 | 現(xiàn)貨 |
---|---|---|---|
規(guī)格 | 5 mg | 貨號 | HY-P99604 |
應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務(wù)。
CAS No. : 2420563-99-9
產(chǎn)品活性:Cilgavimab (AZD-1061; COV2-2130) is a humanized SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection.
研究領(lǐng)域:Anti-infection
作用靶點:SARS-CoV
In Vitro: Cilgavimab and Tixagevimab simultaneously bind to distinct, nonoverlapping epitopes of the SARS-CoV-2 spike-protein (S) receptor-binding domain to potently neutralize the virus.
Cilgavimab exhibits potent monoclonal antibody neutralization activity, and human ACE2-blocking activity, with IC50s of 10-150 ng/mL, and shows binding ability to either trimeric S2Pecto protein or monomeric SRBD with IC50s of 0.1-10 ng/mL.
In Vivo: Cilgavimab (200 μg/mouse; i.p.; before SARS-CoV-2 injection) protects mice from weight loss and reduces the viral burden and levels of inflammation in the lungs.
相關(guān)產(chǎn)品:Antimicrobial agent-10 | SARS-CoV-2-IN-23 | 3CPLro-IN-1 | SP inhibitor 1 | rel-Zotatifin | Antioxidant agent-9 | Regdanvimab | Silymarin | NHC-triphosphate tetraammonium | Grazoprevir potassium salt | Atazanavir | FWM-4 | Amantadine-d6 | Ketotifen fumarate | SARS-CoV-2-IN-27 | MMT5-14 | Tipranavir | Amantadine | Sotrovimab | Antiviral agent 5 | F8-S43-S3 | Ritonavir-d6 | Fluphenazine dimaleate | GNF-2 | SARS-CoV-2-IN-7 | Mpro inhibitor N3 | SARS-CoV-2 Mpro-IN-6 | SARS-CoV-2-IN-32 | Azelastine hydrochloride | XP-59
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標(biāo)記物 | 寡核苷酸 | 抗體 | 點擊化學(xué)
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學(xué)分析檢測分析,藥物篩選等專業(yè)技術(shù)服務(wù);
• 設(shè)有專業(yè)的實驗中心和嚴(yán)格的質(zhì)控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團(tuán)隊跟蹤最新的制藥及生命科學(xué)研究進(jìn)展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機(jī)構(gòu)建立了長期的合作。
(空格分隔,最多3個,單個標(biāo)簽最多10個字符)